Gamida Cell Announces New Translational Data for Nicord® to Be Presented at ASH 2018 Annual Meeting
BOSTON—(BUSINESS WIRE)—Nov. 1, 2018— Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced that new translational data for NiCord®, an investigational cell therapy in Phase 3 clinical development for allogeneic stem cell, or bone marrow, transplant, will be presented at the American Society of Hematology (ASH) 2018 Annual Meeting, which is being held December 1-4 in San Diego, CA.
Details about the poster presentation are as follows:
Presentation Time:Saturday, December 1, 2014, 6:15 p. m. — 8:15 p. m. PT
Title: Rapid and Robust CD4+ and CD8+ T-, NK-, B- and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation
Abstract Number: 2123
Lead Author:Jaap Jan Boelens, M. D., Ph. D., Pediatric Blood and Marrow Transplantation Program, University Medical Center Utrecht, Utrecht, Netherlands
Location:San Diego Convention Center, Hall GH
About NiCord
NiCord, the company’s lead clinical program, is under development as a universal bone marrow transplant solution for patients with high-risk hematologic malignancies. NiCord has demonstrated improved efficacy over standard cord blood, including fewer bacterial and fungal infections and a reduction in duration of hospital stays. NiCord has been granted breakthrough status by the U. S. Food and Drug Administration, making it the first bone marrow transplant alternative to receive this designation. It has also received U. S. and EU orphan drug designation. A Phase 3 study evaluating NiCord in patients with leukemia and lymphoma is ongoing in the United States, Europe and Asia (NCT02730299). For more information on NiCord clinical trials, please visit www. clinicaltrials. gov.
About Gamida Cell
Gamida Cell is a clinical stage biopharmaceutical company leveraging its proprietary technology to develop cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The company is leveraging its nicotinamide-, or NAM-, based cell expansion technology to develop a pipeline of products designed to address the limitations of cell therapies.
View source version on businesswire. com: https://www. businesswire. com/news/home/20181101005046/en/
Source: Gamida Cell
Investor and Media Inquiries:
Gamida Cell
Jaren Irene Madden, 1-617-286-6264
jaren@gamida-cell. com
or
Media Inquiries:
W2O Group
Melanie Higham, 1-617-302-8202
mhigham@w2ogroup. com